Novel composition for treating metabolic syndrome
OwnerChien-Hung Cheninventor
Life of this patent
Estimating the term…
Abstract
The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated Protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.
Claims52
A composition, comprising:
- a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator;
- a second agent that possesses anti-inflammatory activity;
- and
- a third agent that possesses or maintains serotonin activity.
A composition, comprising:
- a first agent selected from the group consisting of metformin, phenformin, buformin, ephedrine, thyroxine, salicylanilide, and salicylic acid;
- a second agent that possesses anti-inflammatory activity;
- and
- a third agent that possesses or maintains serotonin activity.
A method for treating metabolic syndrome, comprising administering to a subject in need thereof an effective amount of a composition containing a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator;
- a second agent that possesses anti-inflammatory activity;
- and a third agent that possesses or maintains serotonin activity.
A method for treating obesity, comprising administering to a subject in need thereof an effective amount of a composition containing a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator;
- a second agent that possesses anti-inflammatory activity;
- and a third agent that possesses or maintains serotonin activity.
A method for treating hypertension, comprising administering to a subject in need thereof an effective amount of a composition containing a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator;
- a second agent that possesses anti-inflammatory activity;
- and a third agent that possesses or maintains serotonin activity.
A method for treating diabetes, comprising administering to a subject in need thereof an effective amount of a composition containing a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator;
- a second agent that possesses anti-inflammatory activity;
- and a third agent that possesses or maintains serotonin activity.
A method for treating Parkinson's disease, comprising administering to a subject in need thereof an effective amount of a composition containing a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator;
- a second agent that possesses anti-inflammatory activity;
- and a third agent that possesses or maintains serotonin activity.
A method for treating polycystic ovarian syndrome, comprising administering to a subject in need thereof an effective amount of a composition containing a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an AMPK activator;
- a second agent that possesses anti-inflammatory activity;
- and a third agent that possesses or maintains serotonin activity.
Dependencies are inferred from the claim text.